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Electrophysiologic Effects and Efficacy of Recainam for Sustained 
Ventricular Tachycardia 
Michael de Buitleir, MD, William H. Kou, MD, Steven 
and Fred Morady, MD 
R ecainam is an investigational antiarrhythmic drug recently introduced into clinical testing. It is a phe- 
nylalkyl urea derivative that produces a concentration- 
dependent decrease in membrane responsiveness and 
maximal upstroke velocity.’ The reduction in maximal 
upstroke velocity displays use-dependence,’ similar to the 
class 1A drugs. However, unlike class 1A drugs, but 
similar to class 1B agents, recainam does not prolong 
action potential duration.’ Other studies demonstrated 
that recainam slows conduction with minimal effect on 
ventricular refractoriness,2 effects consistent with a class 
1C antiarrhythmic action. Thus, these preliminary inves- 
tigations suggested that recainam possesses a unique elec- 
trophysiologic profile with properties of each of the 3 
class 1 subclasses. Other preclinical studies have demon- 
strated recainam’s efficacy in suppressing ventricular ar- 
rhythmias in the postinfarction dog model3 and initial 
clinical studies have demonstrated that it is highly effec- 
tive in suppressing ventricular premature complexes.4-6 
However, no studies to date have reported the electro- 
physiologic effects of recainam in patients with sustained 
ventricular tachycardia (VT). Such is the purpose of this 
report. 
The subjects of this study were 10 men who had 
unimorphic VT inducible by programmed ventricular 
stimulation. Their mean age was 60 f 12 years (range 34 
to 74). All 10 patients had had a myocardial infarction. 
The mean left ventricular ejection fraction by contrast or 
radionuclide ventriculography was 0.38 f 0.05 (range 
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TABLE I Electrophysiologic Effects of Oral Recainam in 10 
Patients 
Baseline Oral Recainam P value 







Atrial FRP, DCL 500 
Atrial ERP. DCL 500 
AVN FRP, DCL 500 
AVN ERP, DCL 500 
RVA ERP. DCL 600 
RVA ERP, DCL 400 
RVOT ERP, DCL 600 
RVOT ERP, DCL 400 
920 k 213 
102 f 26 
52f12 
109 % 16 
l,llOf:206 
208 f 103 
455 f 77 
264 f 34 
225 f 14 
444f66 




250 f 14 
767 f 173 
127 f 47 
62f 13 
126 f 19 
1,088 f 321 
367% 241 
4584 117 
247 zk 26 
192 f 33 
468f 113 
356f 131 
263 f 29 
254 z!z 25 

















All measurements are in ms. 
DCL = drive cycle length; ERP = effective refractory period; FRP = functional 
refractory period; NS = not significant: RVA = right ventricular apex; RVOT = right 
ventricular outflow tract; SNRT = sinus node recovery time: SNRT, = corrected 
SNRT: WBB = longest cycle length at which atrioventricular nodal Wenckebach block 
occurred during overdrive atrial pacing. 
0.32 to 0.47). The indication for the electrophysiologv 
study was sustained unimorphic VT in 7 patients, cardi- 
ac arrest in 2 and syncope in 1. The patients hadfailed to 
respond to or had intolerable side effects with a mean of 
2.5 f 1.2 (range 1 to 5) antiarrhythmic drugs before 
treatment with recainam. Exclusion criteria included 
unstable angina, myocardial infarction within 3 months 
before the study and a left ventricular ejection fraction 
KO.30. 
The study protocol was approved by the Institutional 
Review Board and all patients gave written informed 
consent before takingpart in the study. The electrophys- 
iology study was performed with patients in the fasting, 
unsedated state at least 5 half-lives after discontinuation 
of all antiarrhythmic drugs. A detailed description of the 
electrophysiology study protocol has been published 
previously.7 After a rest period of 5 minutes, baseline 
electrophysiologic parameters were measured (Table I). 
Ventricular programmed stimulation was performed at 
the right ventricular apex and right ventricular outflow 
tract at 2 drive rates (600 or 500 and 400 ms) with up to 
3 extrastimuli. Sustained VT was defined as VT lasting 
>30 seconds or requiring intervention for termination. 
After the baseline electrophysiology study all patients 
were treated with oral recainam. Allpatients had a base- 
line 48-hour ambulatory electrocardiographic recording 
(Cardio Data Systems) before commencing treatment 
with recainam. At the time of thefollow-up electrophysi- 
ology study, 9 patients were receiving 400 mg every 8 
hours and 1 patient 600 mg every 8 hours. The follow-up 
electrophysiology study was performed after a mean of 
10 f 3 doses of recainam, between the fourth and eighth 
hours of the dosing interval (mean plasma concentration 
2.7 f 1.4 pg/ml). 
The patients underwent hematologic and biochemi- 
cal screening and a 12-lead electrocardiogram during 
the baseline state and during treatment with recainam. 
Patients in whom the induction. of sustained VT was 
suppressed by recainam had a 24-hour ambulatory elec- 
trocardiogram before hospital discharge and were eligi- 
ble to continue to receive recainam in the long-term out- 
patient phase of the study. This phase of the study incor- 
porated clinic visits every month for the first 6 months 
and every 3 months thereafter. A resting 12-lead elec- 
trocardiogram and 24-hour ambulatory electrocardio- 
graphic recording were obtained at each clinic visit. All 
data were analyzed using a paired t test and arepresent- 
ed as mean f 1 standard deviation. A p value of CO.05 
was considered significant. 
Recainam significantly shortened the sinus cycle 
length and atria1 effective refractory period and signifi- 
cantly prolonged the AH and HV intervals and QRS 
duration (Table I). None of the other electrophysiologic 
parameters was altered signiJcantly. After treatment 
with recainam, sustained VT was no longer inducible in 1 
of 10 patients (no. 7) (Table II). Overall, the mean cycle 
length of induced VT was prolonged signgicantly by 
recainam from 309 f 49 ms baseline to 383 f 83 ms (p 
<0.05). One patient (no. 6) was not included in this 
analysis because VTs of different morphologies were 
induced in the baseline and follow-up studies. 
Examination of the 12-lead electrocardiograms re- 
vealed that the sinus rate was significantly faster with 
recainam compared to baseline (80 f 16 us 69 f 10 
beats/min; p <O.OS). Recainam significantly increased 
the PR interval (0.22 f 0.04 us 0.18 f 0.03 seconds; p 
<O.OOl) and QRS duration (0.13 f 0.02 us 0.11 f 0.02 
seconds;p <O.Ol). There was no significant change in the 
QT interval. 
The 1 patient (no. 7) in whom the induction of sus- 
tained VT was suppressed by recainam entered the long- 
term outpatient phase of the study. He continues to re- 
ceive 1,200 mg of recainam daily and remains well after 
18 months of treatment. However, his serial 24-hour 
ambulatory electrocardiograms have revealed frequent 
episodes of nonsustained VT associated with minimal 
symptoms. In the baseline state, this patient had virtual- 
ly incessant VT. No adverse reactions were noted during 
treatment of any patient with recainam and no signify- 
cant side effects were reported. 
This study demonstrates that recainam significantly 
prolongs the resting AH and I-IV intervals and QRS 
duration but does not lengthen the atrial, atrioventricular 
nodal or ventricular refractory periods. These data con- 
firm that recainam’s main electrophysiologic action is to 
prolong conduction time without altering refractoriness. 
Although preclinical studies suggested that recainam has 
properties of each of the 3 class I subclasses, the present 
results suggest that its class 1C properties predominate in 
the clinical setting. With recainam, resting sinus cycle 
length was significantly shorter. This finding has been 
noted previously” and may be secondary to a mild nega- 
tive inotropic or anticholinergic action. In the present 
study recainam produced a barely significant reduction in 
atria1 effective refractory period. This finding could not 
be explained on the basis of its known electrophysiologic 
properties and must await reexamination in further clini- 
cal studies. 
In 1 of 10 patients, recainam prevented the induction 
of sustained VT, which had been unresponsive to conven- 
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tional antiarrhythmic drug therapy. This patient has re- 
mained well over a follow-up period of 18 months. Al- 
though he has continued to show episodes of nonsustained 
VT on 24-hour ambulatory recordings during follow-up, 
these episodes are shorter, slower and less frequent than 
during the baseline state when his VT was virtually inces- 
sant. In patients in whom VT remained inducible, re- 
cainam significantly slowed the mean VT rate from 194 
to 157 beats/min (p <0.05). However, none of these 
patients was treated for a long term with recainam be- 
cause this partial response was deemed inadequate. A 
notable observation in our study was the absence of sig- 
nificant side effects. Recainam was well tolerated by all 
10 patients during short-term administration and by the 1 
patient in the long-term study. In particular, no patient 
developed signs or symptoms of congestive heart failure. 
These results are similar to those found in previous stud- 
ies of ventricular premature complex suppression.4-6 
In conclusion, recainam may occasionally suppress 
the induction of sustained VT in patients who have failed 
to respond to other antiarrhythmic drugs. It appears to be 
well tolerated during short-term administration. Further 
studies will be necessary to determine its long-term effi- 
cacy and safety in patients with sustained VT. 
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Automatic Implantable Cardioverter Defibrillator Implantation for 
Malignant Ventricular Arrhythmias Associated with Congential Heart 
Disease 
Mary A. Kral, PA-C, Henry M. Spotnitz, MD, Alan Hordof, MD, J. Thomas Bigger, Jr., MD, 
Jonathan S. Steinberg, MD, and Frank D. Livelli, Jr., MD 
T he prognosis for patients with congenital cardiac abnormalities can be improved by surgical correction 
of hemodynamics. With’ or without2 surgery, sudden 
death from malignant ventricular arrhythmias is an im- 
portant potential problem in congenital heart disease. 
Pharmacologic arrhythmia control may be limited by 
side effects, noncompliance or unreliable indexes predic- 
tive of drug efficacy. The automatic implantable cardio- 
verter difibrillator (AICD) is a potential alternative. The 
incidence of arrhythmic death is <2% per year following 
AICD implant3 in adults with ventricular arrhythmias 
refractory to medical management. This success rate fa- 
vors AICD therapy in selected patients with congenital 
heart disease. We present 4 such cases (Table I) and 
discuss their management. 
The first patient (no. 1) experienced no spontaneous 
arrhythmia. Intervention was prompted by sudden death 
in 2 siblings within 2 years. Electrophysiologic study 
revealed ventricular fibrillation during both atria1 and 
ventricular stimulation. A left paraseptal accessory 
pathway with short anterograde refractory period was 
also demonstrated. Intervention was required in the re- 
maining 3 patients (nos. 2, 3 and 4) because of cardiac 
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arrest during daily activities. Arrhythmias were not in- 
ducible in the electrophysiology laboratory to guide 
therapy. One of these patients (no. 4) experienced nearly 
fatal failure of empiric management at another hospital. 
AICD implantation was recommended as more likely to 
provide long-term survival than empiric drug therapy or 
cardiac transplantation. Direct surgical ablation was not 
attempted because of inability to map the site of origin of 
the ventricular arrhythmias. 
Preoperative evaluation included catheter studies of 
electrophysiology and hemodynamics, as well as exer- 
cise testing to define maximal heart rate. The surgical 
approach was dictated by factors including residual 
pathologic anatomy and physiology, surgical adhesions, 
shunts and prostheses. The need for accessory pathway 
ablation (no. I), aortic coarctation repair (no. 2) and 
transvenous pacemaker insertion (no. 3) were specific 
issues in these patients. A bipolar dual chamber pacing 
system, physical separation of the pacing electrodes 
from AICD rate sensing electrodes and reduced pacing 
amplitude inpatient no. 3 avoided undesirablepacemak- 
er-AICD interaction.4 
Since defibrillation thresholds can increase postoper- 
atively, AICDfunction was retested I week after implan- 
tation. AICD failure during this test inpatient no. 2 was 
corrected by implantation of a transvenous spring-coil 
electrode, although patch-coil systems are usually less 
effective than large patch systems.j Postpericardiotomy 
syndrome in 2 patients (nos. 1 and 4) responded to anti- 
